Peter Hutt BW.png

Peter Barton Hutt, Esq.

Mr. Peter Barton Hutt, J.D., LLB, LLM, Esq. serves as an Advisor of InCube Labs, LLC. Mr. Hutt serves as a Senior Advisor at Kearny Venture Partners. He serves as an Advisor of Ovascience, Inc. He serves as a Senior Counsel at Covington & Burling LLP and has been its Partner since 1968, except for the period from 1971 to 1975. He serves as an Advisor of Akebia Therapeutics, Inc. He served as Special Advisor to the Chairman at NuVim Inc. and specifically provides consultation on food and drug administration matters. He has been an attorney of Covington & Burling LL since 1960. He served as Scientific Advisor at Axcella Health, Inc. He started his practice of law at Covington in October 1960. Mr. Hutt served as Special Advisor of Gelesis, Inc. He served as Special Advisor at Catheter Connections, Inc. He specialized in food and drug law and trade association law at Catheter Connections. He served as an Advisor at Living Proof, Inc. He served as Regulatory Advisor at Vybion, Inc. He served as an Advisor at PureTech Health plc. He served as FDA General Counsel and Chief Counsel. From 1971 to 1975, he served as the Chief Counsel at United States Food and Drug Administration. In September 1975, he returned to private law practice at Covington and Burling. Mr. Hutt served as the Chairman and Member of Regulatory Advisory Board at PPD Dermatology, Inc. He serves as a Vice Chairman of Foundation for Biomedical Research and the International Board of the Scripps Institutions of Medicine and Science. He has been an Independent Director of Flex Pharma, Inc. since March 2014. Mr. Hutt serves as a Director and Member of Strategic Advisory Board of Longwood Founders Management, LLC. Mr. Hutt has been a Director of Immunomedics, Inc. since March 3, 2017. He has been a Director Sparta Pharmaceuticals since December 1991. He serves as a Director of Nanomedical Systems, Inc., Axcella Health, Inc., Seventh Sense Biosystems, Inc., Life Line Screening of America, LLC and Living Proof, Inc. He serves as a Director of Moderna Therapeutics, Inc., California Life Sciences Association, Microban International, Ltd., and CV Therapeutics Inc. Mr. Hutt has been a Director of Suneva Medical, Inc. since October 2014 and Selecta Biosciences, Inc. since 2016. He has been an Independent Director of Concert Pharmaceuticals, Inc. since December 2006 and served as its Member of Product Advisory Board. He serves as a Director and Member of Strategic Advisory Board of Longwood Founders Fund, L.P. He has been a Director of Axcella Health, Inc. (Also known as Pronutria Biosciences, Inc.) since December 8, 2014. He has been an Independent Director of Q Therapeutics, Inc. since July 2002. He serves as a Director of the Food and Drug Law Institute. He served as a Director of Rubius Therapeutics, Inc. He has been a Director of Q Holdings, Inc. since October 13, 2011. He served as an Independent Director at XOMA Corporation since May 2005 until May 24, 2017. He serves as a Director of Proterris, Inc. He serves as a Member of Scientific Advisory Board at AeroDesigns, Inc. Mr. Hutt serves as a Member of Industry Advisory Board at New Leaf Venture Partners, L.L.C. He serves as a Member of Scientific Advisory Board of Kala Pharmaceuticals, Inc. He serves as a Member of the Board of Advisors of InCube Ventures, LLC. Mr. Hutt serves as a Member of Regulatory Advisory Board and Director at Cognetix, Inc. He serves as a Member of the Scientific Advisory Board at Alnara Pharmaceuticals, Inc. Mr. Hutt serves as a Member of Advisory Board at Sherbrooke Capital Health and Wellness, L.P., Sherbrooke Health and Wellness Capital Fund II, L.P., Mailman School of Public Health, Columbia University, Western Institutional Review Board, Inc., Burrill Nutraceuticals Capital Fund, L.P., Polaris Venture Partners, Inc., Sherbrook Capital Health and Wellness Fund and the Sprout Group. He serves as a Member of Advisory Board at First Aid Beverages, Inc. He serves as a Member of Advisory Board at Polaris Partners. He serves as a Trustee of Keck Graduate Institute Of Applied Life Sciences. He serves as a Trustee of Institute for Health Policy Analysis. He serves on the Advisory Board of Columbia University School of Public Health. He serves as a Member of Advisory Board at Whole Biome, Inc. He serves as a Member of Advisory Board at Rani Therapeutics, LLC. He served as Director of Celera Corporation/Celera Genomics since August 19, 2008 and DNIB Unwind, Inc. (also known as BIND Therapeutics, Inc.) since 2008. He served as a Member of the Scientific Advisory Board at Quantum Designs, LLC. He served as a Member of Scientific Advisory Board at Sirtris Pharmaceuticals, Inc. and Pulmatrix, Inc. He served as a Director at ISTA Pharmaceuticals, Inc. since November 2002. Mr. Hutt served as Director of BIND Biosciences, Inc. from 2008 to 2016. He served as a Non-Executive Director of DBV Technologies S.A. from February 2009 to June 23, 2015. He served as a Member of the Advisory Board at Vybion, Inc. Mr. Hutt served as an Independent Director of Momenta Pharmaceuticals Inc. from June 2001 to December 31, 2014 and also served as its Member of Regulatory Advisory Board until December 31, 2014. He served as a Director of Seres Therapeutics, Inc. since May 2013 until June 20, 2017. Mr. Hutt served as an Independent Director at Endotis Pharma SA. He served as a Member of Business Advisory Board at Genocea Biosciences, Inc. He has been an Independent Director of Favrille Inc., from November 2003 to June 24, 2008. Mr. Hutt served as a Director of Tarveda Therapeutics, Inc., Endo Pharmaceuticals Solutions Inc., NuVim Inc., Entegrion, Inc., Biogen Inc., Indevus Pharmaceuticals Inc., Parexel International Corporation, Cell Genesys, Inc., VIVUS Inc. and Emisphere Technologies, Inc. He served as a Director of Grace 2, Inc. since October 13, 2011. He served as a Director of MMRGlobal, Inc., until June 24, 2008, Introgen Therapeutics Inc. from August 24, 2004 to December 2, 2008, Phase Forward Inc. from October 1999 to June 30, 2005, Quick-Med Technologies Inc. from April 2002 to November 5, 2003 and Gilead Palo Alto, Inc., from August 2000 to May 18, 2008. Mr. Hutt has been a Member of the National Academy of Medicine (formerly called the Institute of Medicine) since it was formed in 1971. He serves as a Member of the Proseed Committee of ProSeed Capital Holdings, C.V.A. Mr. Hutt advises and represents trade associations including the Pharmaceutical Research Manufacturers of America and the Consumer Healthcare Products Association and both large and small companies in the food, drug, biologic, biotechnology, cosmetic and medical device industries. Mr. Hutt serves on the Panel on the Administrative Restructuring of the National Institutes of Health. He served on IOM Roundtable for the Development of Drugs and Vaccines Against AIDS and five Office of Technology Assessment advisory panels.